A detailed history of Freestone Grove Partners LP transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Freestone Grove Partners LP holds 197,747 shares of DVAX stock, worth $2.19 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
197,747
Previous 37,456 427.94%
Holding current value
$2.19 Million
Previous $372 Million 428.48%
% of portfolio
0.01%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$9.36 - $11.36 $1.5 Million - $1.82 Million
160,291 Added 427.94%
197,747 $1.96 Billion
Q2 2025

Aug 14, 2025

SELL
$9.4 - $12.87 $113,194 - $154,980
-12,042 Reduced 24.33%
37,456 $372 Million
Q1 2025

May 15, 2025

BUY
$12.39 - $14.4 $613,280 - $712,771
49,498 New
49,498 $642 Million

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.4B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Freestone Grove Partners LP Portfolio

Follow Freestone Grove Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Freestone Grove Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Freestone Grove Partners LP with notifications on news.